Table 2.
Comparison of costs (reimbursement amounts, in Euros) associated with hospital and outpatient use, per patient, over a 2-year period after the index date (patients with uncontrolled severe asthma vs general population and asthmatic control cohorts)
| Costs per patient | Cohort of patients with uncontrolled severe asthma (n=739) |
General population cohort (n=2217) |
P value | Asthmatic control cohort (n=739) |
P value | |
| Hospitalisation | Mean (σ) | 8163 (20 669) | 1800 (7991) | p<0.0001 | 3589 (13 702) | p<0.0001 |
| Median(Q1-Q3) | 426 (0–5854) | 0 (0–0) | 0 (0–1284) | |||
| Min–max | 0–246 483 | 0–176 423 | 0–190 457 | |||
| ED visit without hospitalisation | Mean (σ) | 12 (28) | 6 (18) | p<0.0001 | 9 (33) | p<0.0001 |
| Median (Q1–Q3) | 0 (0–25) | 0 (0–0) | 0 (0–0) | |||
| Min–max | 0–319 | 0–273 | 0–671 | |||
| Medical visits | Mean (σ) | 643 (1068) | 368 (437) | p<0.0001 | 496 (658) | p<0.0001 |
| Median (Q1–Q3) | 491 (278–786) | 265 (113–499) | 376 (217–612) | |||
| Min–max | 0–24 882 | 0–6861 | 0–11 547 | |||
| Laboratory tests | Mean (σ) | 241 (321) | 154 (266) | p<0.0001 | 203 (285) | p=0.0131 |
| Median (Q1–Q3) | 145 (53–295) | 85 (0–180) | 126 (54–237) | |||
| Min–max | 0–3137 | 0–5727 | 0–2461 | |||
| Paramedical visits | Mean (σ) | 1406 (4827) | 747 (2986) | p<0.0001 | 968 (3236) | p<0.0001 |
| Median (Q1–Q3) | 176 (12–689) | 18 (0–288) | 42 (0–469) | |||
| Min–max | 0–65 527 | 0–50 060 | 0–36 145 | |||
| Medications | Mean (σ) | 3076 (9131) | 199 (410) | p<0.0001 | 721 (747) | p<0.0001 |
| Median (Q1–Q3) | 1525 (1037–2185) | 58 (12–220) | 523 (246–957) | |||
| Min–max | 0–95 453 | 0–5855 | 0–9472 | |||
| Total costs | Mean (σ) | 14 020 (24 076) | 3564 (9540) | p<0.0001 | 6418 (15 109) | p<0.0001 |
| Median (Q1–Q3) | 4625 (2492–13 897) | 825 (297–2286) | 1905 (1020–4906) | |||
| Min–max | 105–253 160 | 0–190 380 | 0–193 294 |
ED, emergency department.